Pharmaceuticals & Therapeutics

A new wellness program by celebrity psychiatrist Dr. Daniel Amen is launching in churches, blending neuroscience with scripture to fight a national health crisis.

Bradford Health Services acquires Indiana's Parkdale Center, marking a major Midwest expansion and boosting specialized, confidential care for professionals.

The company's revenue skyrocketed, but SEC filings reveal a story of significant liquidity risks and a bold gamble on the booming wellness market.

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

A $10,000 gift born from tragedy funds cutting-edge science, showing how community action is vital in the quest to end life-threatening food allergies.

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

A new EU directive to clean wastewater could make essential generic medicines unprofitable, sparking fears of widespread shortages across the continent.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

With stockholder approval, Abbott's acquisition of Exact Sciences is set to reshape the cancer diagnostics landscape and accelerate early detection.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Guerbet's Elucirem™ gains FDA approval for patients aged 0-2, halving gadolinium exposure in the most vulnerable without sacrificing diagnostic quality.

Dr. Joss Reimer, a veteran of Manitoba's COVID-19 response, takes the helm at PHAC, facing a slate of crises from measles to misinformation.

New data on leronlimab reveals striking long-term survival signals in heavily pretreated mTNBC patients, hinting at a new way to fight the disease.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.